Roche used its diagnostics day to outline a strategy to become an end-to-end oncology solutions provider, spanning early detection through therapy selection and monitoring. Executives highlighted two pending acquisitions: PathAI and Saga Diagnostics, alongside the upcoming launch of its Axelios sequencing instrument. Roche said the $1.05 billion acquisition of PathAI would create “strong synergy” with its Ventana tissue pathology business and with Foundation Medicine. The company also positioned PathAI to support earlier engagement with pharma customers on companion diagnostics. Roche further tied the Saga Diagnostics deal to disease monitoring via Foundation Medicine’s Pathlight MRD technology, which already includes Medicare approval for early-stage breast cancer across subtypes. Separately, Axelios is expected to serve as a growth accelerant for molecular-based testing.